Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection

Fidaxomicin causes less disruption of anaerobic microbiota during treatment of Clostridium difficile infection (CDI) than vancomycin and has activity against many vancomycin-resistant enterococci (VRE). In conjunction with a multicenter randomized trial of fidaxomicin versus vancomycin for CDI treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nerandzic, Michelle M., Mullane, Kathleen, Miller, Mark A., Babakhani, Farah, Donskey, Curtis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388028/
https://www.ncbi.nlm.nih.gov/pubmed/22752860
http://dx.doi.org/10.1093/cid/cis440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388028/
https://www.ncbi.nlm.nih.gov/pubmed/22752860
http://dx.doi.org/10.1093/cid/cis440

Ejemplares similares